Exemestane

also known as Aromasin · Aromasin (exemestane) · Aromasin, exemestane, Pfizer · Baby Exemestane · babyexe · EXE · Exemestane (Aromasin) · Exemestane Tablets · +4 more

Small molecule targets CYP19A1 via inhibition

Developed for: breast cancer · female breast carcinoma · hormone receptor-positive breast cancer · estrogen-receptor positive breast cancer · breast neoplasm · Her2-receptor negative breast cancer · HER2 positive breast carcinoma · progesterone-receptor positive breast cancer
+30 more
· invasive breast carcinoma · breast carcinoma · male breast carcinoma · breast carcinoma in situ · endometrial cancer · metastatic malignant neoplasm · non-small cell lung carcinoma · ovarian cancer · atypical endometrial hyperplasia · breast adenocarcinoma · breast lobular carcinoma · cancer · endometrial carcinoma · endometrial endometrioid adenocarcinoma · exocrine pancreatic carcinoma · metastatic carcinoma in the bone · ovarian carcinoma · ovarian granulosa cell tumor · polycystic ovary syndrome · prostate carcinoma · salivary gland carcinoma · sarcoma · secondary malignant neoplasm · urinary bladder cancer · urothelial carcinoma · uterine corpus endometrial stromal sarcoma · basal-like breast carcinoma · ductal breast carcinoma in situ · luminal B breast carcinoma · prostate cancer
Investigated by: National Cancer Institute (NCI) · Pfizer · Novartis Pharmaceuticals · Fudan University · ETOP IBCSG Partners Foundation · Eli Lilly and Company
+155 more
· UNICANCER · Breast International Group · Cancer and Leukemia Group B · AstraZeneca · City of Hope Medical Center · Dana-Farber Cancer Institute · Institut Claudius Regaud · Merck Sharp & Dohme LLC · NCIC Clinical Trials Group · Agendia · Breast Cancer Research Foundation · Clinical Research Technology S.r.l. · Emory University · European Organisation for Research and Treatment of Cancer - EORTC · GBG Forschungs GmbH · Genentech, Inc. · Georgetown University · International Collaborative Cancer Group · M.D. Anderson Cancer Center · Medical College of Wisconsin · Memorial Sloan Kettering Cancer Center · NSABP Foundation Inc · NYU Langone Health · North Central Cancer Treatment Group · Novartis · Ohio State University Comprehensive Cancer Center · Ottawa Hospital Research Institute · Peking University Cancer Hospital & Institute · Roche Pharma AG · SWOG Cancer Research Network · Spanish Breast Cancer Research Group · Sun Yat-sen University · Susan G. Komen Breast Cancer Foundation · Tianjin Hemay Pharmaceutical Co., Ltd · University of Ulm · University of Washington · iOMEDICO AG · AMS Advanced Medical Services GmbH · ARCAGY/ GINECO GROUP · Abramson Cancer Center at Penn Medicine · Alliance for Clinical Trials in Oncology · Amgen · Amsterdam UMC, location VUmc · Andrea DeCensi · Anhui Provincial Cancer Hospital · Arbeitsgemeinschaft fur Internistische Onkologie · Astellas Pharma Inc · Baylor Breast Care Center · Breast Cancer Trials, Australia and New Zealand · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Calithera Biosciences, Inc · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Cancer Research Campaign Clinical Trials Centre · Cancer Research UK · Cankado GmbH · Catalan Institute of Oncology · Celgene Corporation · Centre Leon Berard · Centre Oscar Lambret · Chinese Academy of Medical Sciences · Chinese PLA General Hospital · Chugai Pharmaceutical · Consorzio Oncotech · Dana-Farber/Brigham and Women's Cancer Center · Dartmouth-Hitchcock Medical Center · Dutch Breast Cancer Research Group · Eastern Cooperative Oncology Group · Eisai Inc. · Ente Ospedaliero Ospedali Galliera · European Institute of Oncology · Federation of Italian Cooperative Oncology Groups · First Affiliated Hospital of Zhejiang University · First Affiliated Hospital, Sun Yat-Sen University · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · all 161 on the full record

Regulatory milestones approvals, filings & regulatory actions · 3 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (2)	US (FDA)	AROMASIN	—	2005-10-05 – 2016-07-25	fda.gov ↗
Approved	US (FDA)	AROMASIN	—	1999-10-21	fda.gov ↗

Trials 172 · started per year

today

US approved 1999

199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 116 trials
Phase 1	NCT07706374	Oct 2026 → Dec 2028 expected	polycystic ovary syndrome	University of North Carolina, Chapel Hill	Recruiting	No outcome recorded
Phase 1	NCT07369505	Dec 2025 → Jun 2026 overdue	breast carcinoma, hepatocellular carcinoma, neuroendocrine neoplasm, renal cell carcinoma +1	SAPU NANO (US) LLC	Recruiting	No outcome recorded
Phase 1	NCT07163481	Oct 2025 → Dec 2026 expected	female breast carcinoma	Hunan Cancer Hospital	Not yet recruiting	No outcome recorded
Phase 1	NCT03554044	Feb 2020 → Dec 2023	Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma, invasive breast carcinoma	University of California, San Francisco	Completed	No outcome recorded
Phase 1	NCT04188548	Dec 2019 → Jun 2020 overdue	breast cancer, endometrial cancer	Eli Lilly and Company	Active not recruiting	No outcome recorded
Phase 1	NCT03959891	May 2019 → Dec 2022 overdue	breast cancer	Massachusetts General Hospital	Active not recruiting	No outcome recorded
Phase 1	NCT03308201	Oct 2017 → Jun 2022	breast cancer	Tianjin Hemay Pharmaceutical Co., Ltd	Completed	No outcome recorded
Phase 1	NCT03125746	Jun 2017 → Oct 2021	breast cancer	Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.	Unknown	No outcome recorded
Phase 1	NCT02833155	Aug 2016 → Jul 2018	breast cancer	Taizhou EOC Pharma Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT02077933	May 2014 → Apr 2019	breast neoplasm, kidney neoplasm, pancreatic neuroendocrine tumor	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT02057133	Mar 2014 → Mar 2021 overdue	breast neoplasm	Eli Lilly and Company	Active not recruiting	No outcome recorded
Phase 1	NCT01857193	Sep 2013 → Mar 2018	breast cancer	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT01870505	May 2013 → Feb 2022	female breast carcinoma	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 1	NCT01664754	Sep 2012 → Jan 2019	non-small cell lung carcinoma	Jonsson Comprehensive Cancer Center	Completed	No outcome recorded
Phase 1	NCT01149356	Oct 2010 → Dec 2012	Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma, male breast carcinoma	National Cancer Institute (NCI)	Terminated	No outcome recorded
Phase 1	NCT00933309	Jul 2009 → Aug 2012	female breast carcinoma	M.D. Anderson Cancer Center	Completed	No outcome recorded

Phase 1/28 trials · 1 met primary · 1 missed
Phase 1/2	NCT03280563	Dec 2017 → Sep 2024	breast neoplasm	Hoffmann-La Roche	Completed	Missed primary
Phase 1/2	NCT02990845	Sep 2017 → Aug 2022	breast carcinoma	National Taiwan University Hospital	Terminated	Met primary
Phase 1/2	NCT02871791	Aug 2016 → Dec 2020	hormone receptor-positive breast cancer	Dana-Farber Cancer Institute	Completed	No outcome recorded
Phase 1/2	NCT02732119	Jun 2016 → Feb 2020	breast cancer	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 1/2	NCT01484041	Apr 2012 → Dec 2015	breast cancer	Georgetown University	Terminated	No outcome recorded
Phase 1/2	NCT00905021	Mar 2010 → Jan 2011	breast cancer	Baylor Breast Care Center	Terminated	No outcome recorded
Phase 1/2	NCT00931450	Mar 2009 → Oct 2011	breast cancer	Catalan Institute of Oncology	Unknown	No outcome recorded
Phase 1/2	NCT00417885	Jun 2007 → Jul 2009	breast cancer	Pfizer	Terminated	No outcome recorded
Phase 291 trials · 4 met primary · 4 missed
Phase 2	NCT07826052	Sep 2026 → Sep 2031 expected	breast cancer	Fudan University	Not yet recruiting	No outcome recorded
Phase 2	NCT07796880	Sep 2026 → Sep 2028 expected	hormone receptor-positive breast cancer	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Recruiting	No outcome recorded
Phase 2	NCT07499999	Sep 2026 → Aug 2027 expected	ATM-related cancer predisposition, BRCA2-related cancer predisposition, CHEK2-related cancer predisposition, atypical lobular breast hyperplasia +1	Dana-Farber Cancer Institute	Not yet recruiting	No outcome recorded
Phase 2	NCT07618923	Jun 2026 → Jun 2028 expected	hormone receptor-positive breast cancer	Tang-Du Hospital	Not yet recruiting	No outcome recorded
Phase 2	NCT07395336	May 2026 → Dec 2028 expected	breast cancer	European Institute of Oncology	Recruiting	No outcome recorded
Phase 2	NCT07527806	May 2026 → May 2029 expected	breast cancer	Peking University Cancer Hospital & Institute	Not yet recruiting	No outcome recorded
Phase 2	NCT07483307	Mar 2026 → Mar 2030 expected	Her2-receptor negative breast cancer, breast lobular carcinoma, estrogen-receptor positive breast cancer	Memorial Sloan Kettering Cancer Center	Recruiting	No outcome recorded
Phase 2	NCT07300215	Dec 2025 → Nov 2027 expected	breast cancer	The First Affiliated Hospital of Bengbu Medical University	Not yet recruiting	No outcome recorded
Phase 2	NCT07299890	Dec 2025 → Nov 2027 expected	breast cancer	Anhui Provincial Cancer Hospital	Not yet recruiting	No outcome recorded
Phase 2	NCT06364267	Oct 2025 → Jan 2027 expected	breast cancer	Andrea DeCensi	Recruiting	No outcome recorded
Phase 2	NCT07179939	Sep 2025 → Dec 2030 expected	HER2 positive breast carcinoma	Fudan University	Not yet recruiting	No outcome recorded
Phase 2	NCT06979596	Aug 2025 → Nov 2027 expected	cancer	Merck Sharp & Dohme LLC	Recruiting	No outcome recorded
Phase 2	NCT06970912	Aug 2025 → Dec 2029 expected	female breast carcinoma, hormone receptor-positive breast cancer	Peking University People's Hospital	Recruiting	No outcome recorded
Phase 2	NCT07810088	Jun 2025 → Jun 2028 expected	hormone receptor-positive breast cancer	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Recruiting	No outcome recorded
Phase 2	NCT06630325	Jun 2025 → Mar 2026	exocrine pancreatic carcinoma, female breast carcinoma, ovarian carcinoma, prostate carcinoma +1	OHSU Knight Cancer Institute	Terminated	No outcome recorded
Phase 2	NCT06361940	Sep 2024 → Dec 2028 expected	breast cancer	Medical College of Wisconsin	Recruiting	No outcome recorded
Phase 2	NCT06957379	Feb 2024 → Jun 2025 overdue	hormone receptor-positive breast cancer	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Active not recruiting	No outcome recorded
Phase 2	NCT06169124	Feb 2024 → May 2027 expected	ovarian granulosa cell tumor	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 2	NCT06837792	Oct 2023 → Oct 2026 expected	Her2-receptor negative breast cancer	Yonsei University	Recruiting	No outcome recorded
Phase 2	NCT06145308	Aug 2023 → Jul 2028 expected	salivary gland carcinoma	Peking Union Medical College	Recruiting	No outcome recorded
Phase 2	NCT05826964	Jun 2023 → Jul 2026 overdue	Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer	University of Miami	Active not recruiting	No outcome recorded
Phase 2	NCT05297617	Oct 2022 → Nov 2030 expected	breast cancer	UNICANCER	Recruiting	No outcome recorded
Phase 2	NCT05411380	Oct 2022 → Apr 2024	breast cancer	wang shusen	Unknown	No outcome recorded
Phase 2	NCT05467891	Sep 2022 → Aug 2028 expected	hormone receptor-positive breast cancer	Oana Danciu	Recruiting	No outcome recorded
Phase 2	NCT04997798	Sep 2022 → Dec 2024	HER2 positive breast carcinoma, estrogen-receptor positive breast cancer	First Affiliated Hospital of Zhejiang University	Unknown	No outcome recorded
Phase 2	NCT05150652	Feb 2022 → Dec 2025	Her2-receptor negative breast cancer	Irada Ibrahim-zada	Completed	No outcome recorded
Phase 2	NCT05969184	Dec 2021 → Apr 2026	breast neoplasm	Peking University Cancer Hospital & Institute	Completed	No outcome recorded
Phase 2	NCT04383275	Aug 2021 → May 2025 overdue	breast cancer	Fudan University	Recruiting	No outcome recorded
Phase 2	NCT04965688	Aug 2021 → Mar 2024	Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer	Inova Health Care Services	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT04858516	Apr 2021 → Apr 2024	HER2 positive breast carcinoma	Guangdong Provincial People's Hospital	Unknown	No outcome recorded
Phase 2	NCT04569747	Jan 2021 → Mar 2029 expected	HER2 positive breast carcinoma, hormone receptor-positive breast cancer, invasive breast carcinoma	Dana-Farber Cancer Institute	Active not recruiting	No outcome recorded
Phase 2	NCT04465097	Jul 2020 → Oct 2023	breast cancer	First Affiliated Hospital, Sun Yat-Sen University	Completed	No outcome recorded
Phase 2	NCT04272801	Apr 2020 → Jun 2024 overdue	female breast carcinoma	Shayna Showalter, MD	Active not recruiting	No outcome recorded
Phase 2	NCT04088110	Nov 2019 → Nov 2021	HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer	Fuzhou General Hospital	Unknown	No outcome recorded
Phase 2	NCT04129216	Feb 2019 → Nov 2022	breast cancer	Johns Hopkins University	Completed	No outcome recorded
Phase 2	NCT03691493	Feb 2019 → Oct 2022	Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma, metastatic carcinoma in the bone +1	Emory University	Completed	No outcome recorded
Phase 2	NCT03624244	Jan 2019 → Jan 2028 expected	uterine corpus endometrial stromal sarcoma	Centre Leon Berard	Recruiting	No outcome recorded
Phase 2	NCT02666105	Sep 2018 → Feb 2022	non-small cell lung carcinoma	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 2	NCT03300557	Nov 2017 → Dec 2023	atypical endometrial hyperplasia, endometrial carcinoma, endometrial endometrioid adenocarcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT04659551	Oct 2017 → May 2020	breast cancer	Veneto Institute of Oncology IRCCS	Completed	No outcome recorded
Phase 2	NCT03272477	Oct 2017 → Jul 2020	breast cancer	Palleos Healthcare GmbH	Completed	Met primary
Phase 2	NCT03179904	Aug 2017 → Jul 2024	HER2 positive breast carcinoma, female breast carcinoma	Mayo Clinic	Completed	No outcome recorded
Phase 2	NCT02788201	Mar 2017 → Oct 2019	urinary bladder cancer, urothelial carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT02997995	Feb 2017 → Jul 2019	estrogen-receptor positive breast cancer	UNICANCER	Completed	No outcome recorded
Phase 2	NCT03219476	Feb 2017 → Feb 2020	invasive breast carcinoma	Medical College of Wisconsin	Completed	No outcome recorded
Phase 2	NCT02476786	Jan 2017 → Jan 2027 expected	breast cancer	Washington University School of Medicine	Recruiting	No outcome recorded
Phase 2	NCT02598557	Dec 2016 → Oct 2019	breast carcinoma in situ	National Cancer Institute (NCI)	Completed	Met primary
Phase 2	NCT02894398	Sep 2016 → Feb 2023	hormone receptor-positive breast cancer	iOMEDICO AG	Completed	No outcome recorded
Phase 2	NCT02592746	Jun 2016 → Jun 2021	breast cancer	Samsung Medical Center	Unknown	Met primary
Phase 2	NCT02689921	Apr 2016 → Dec 2018	breast neoplasm	Midwestern Regional Medical Center	Unknown	No outcome recorded
Phase 2	NCT02648477	Mar 2016 → Apr 2022	estrogen-receptor positive breast cancer, progesterone-receptor positive breast cancer, triple-negative breast carcinoma	City of Hope Medical Center	Completed	No outcome recorded
Phase 2	NCT02188745	Mar 2016 → Jan 2024	breast cancer	Dartmouth-Hitchcock Medical Center	Completed	No outcome recorded
Phase 2	NCT03204734	Jan 2016 → Dec 2020	breast cancer	Zhejiang Cancer Hospital	Unknown	No outcome recorded
Phase 2	NCT02910050	Jan 2016 → Sep 2018	breast cancer	Xu fei	Unknown	Missed primary
Phase 2	NCT02448420	Jul 2015 → Sep 2023	breast cancer	SOLTI Breast Cancer Research Group	Completed	No outcome recorded
Phase 2	NCT02603679	Feb 2015 → Jul 2021 overdue	estrogen-receptor positive breast cancer	Thomas Hatschek	Active not recruiting	Missed primary
Phase 2	NCT02049957	Feb 2014 → Jun 2018	female breast carcinoma	Calithera Biosciences, Inc	Completed	No outcome recorded
Phase 2	NCT02028364	Jan 2014 → Jul 2021	breast cancer	Jules Bordet Institute	Completed	No outcome recorded
Phase 2	NCT01989780	Jan 2014 → Jun 2018	breast cancer	Japan Breast Cancer Research Group	Completed	Met primary
Phase 2	NCT02007512	Dec 2013 → Sep 2016	breast cancer	Pfizer	Completed	Mixed
Phase 2	NCT01963481	Sep 2013 → Oct 2017	metastatic malignant neoplasm	NYU Langone Health	Completed	No outcome recorded
Phase 2	NCT01698918	Mar 2013 → Dec 2015	hormone receptor-positive breast cancer	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT02549430	Oct 2012 → Feb 2017	breast cancer	Fondazione Sandro Pitigliani	Completed	No outcome recorded
Phase 2	NCT01627067	Sep 2012 → Feb 2019	breast cancer	M.D. Anderson Cancer Center	Terminated	No outcome recorded Stop: Business
Phase 2	NCT01594216	Apr 2012 → Apr 2016	estrogen-receptor positive breast cancer	Abramson Cancer Center at Penn Medicine	Completed	No outcome recorded
Phase 2	NCT01381874	Aug 2011 → Jul 2014	estrogen-receptor positive breast cancer	Janssen Research & Development, LLC	Completed	Missed primary
Phase 2	NCT01431053	Jul 2011 → Jul 2014	breast cancer	Chinese Academy of Medical Sciences	Unknown	No outcome recorded
Phase 2	NCT01924078	Oct 2010 → Mar 2015	breast cancer	Fudan University	Unknown	No outcome recorded
Phase 2	NCT01151046	Jun 2010 → Jun 2014	Her2-receptor negative breast cancer	Merrimack Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT01005641	Dec 2009 → Oct 2011	breast cancer	National Cancer Institute, Naples	Withdrawn	No outcome recorded
Phase 2	NCT00941330	Jul 2009 → May 2015	breast cancer	Emory University	Completed	No outcome recorded
Phase 2	NCT00793546	Feb 2009 → Jun 2010	female breast carcinoma	Pfizer	Terminated	No outcome recorded
Phase 2	NCT00810797	Dec 2008 → Jun 2019	breast cancer	City of Hope Medical Center	Completed	No outcome recorded
Phase 2	NCT00674557	Jun 2008 → Mar 2009	breast cancer	Cancer Research UK	Terminated	No outcome recorded
Phase 2	NCT00687648	May 2008 → Apr 2010	female breast carcinoma	National Cancer Centre, Singapore	Unknown	No outcome recorded
Phase 2	NCT00615524	Apr 2008 → Nov 2012	hormone receptor-positive breast cancer	GlaxoSmithKline	Withdrawn	No outcome recorded Stop: Enrollment
Phase 2	NCT00432172	Apr 2007 → Sep 2010	breast cancer	Spanish Breast Cancer Research Group	Completed	Missed primary
Phase 2	NCT00201864	Sep 2005 → Jun 2012	breast cancer	Ohio State University Comprehensive Cancer Center	Completed	No outcome recorded
Phase 2	NCT00194792	Aug 2005 → Jul 2011	Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma, progesterone-receptor positive breast cancer	University of Washington	Terminated	No outcome recorded
Phase 2	NCT01965080	Mar 2004 → Feb 2009	endometrial cancer	Nordic Society of Gynaecological Oncology - Clinical Trials Unit	Completed	No outcome recorded
Phase 2	NCT00073073	Nov 2003 → Dec 2011	breast neoplasm	Georgetown University	Completed	No outcome recorded
Phase 2	NCT00201773	Jul 2003 → Nov 2007	female breast carcinoma	Ohio State University Comprehensive Cancer Center	Completed	No outcome recorded
Phase 2	NCT00261027	Jan 2003 → Jul 2007	ovarian cancer	Ottawa Hospital Research Institute	Completed	No outcome recorded
Phase 2	NCT00057993	Jul 2002 → Aug 2004	breast cancer	Northwestern University	Withdrawn	No outcome recorded Stop: Enrollment
Phase 2	NCT00040014	Jun 2002 → Dec 2006	breast neoplasm	Pfizer	Terminated	No outcome recorded
Phase 2	NCT01831076	Apr 2002 → Feb 2013	female breast carcinoma	University of Colorado, Denver	Completed	No outcome recorded
Phase 2	NCT00919399	Jan 2002 → Jun 2006	breast neoplasm	Institut Claudius Regaud	Completed	No outcome recorded
Phase 2	NCT00174343	Nov 2001 → Sep 2006	breast cancer	Pfizer	Completed	No outcome recorded
Phase 2	NCT00010010	Jun 2000 → May 2001	breast cancer	NYU Langone Health	Completed	No outcome recorded
Phase 2	NCT00080613	—	female breast carcinoma	Robert H. Lurie Cancer Center	Withdrawn	No outcome recorded
Phase 2	NCT02025712	? → Aug 2016	hormone receptor-positive breast cancer	Organisation for Oncology and Translational Research	Unknown	No outcome recorded

Phase 2/33 trials
Phase 2/3	NCT06009627	Apr 2023 → Mar 2025	breast cancer	Tianjin Medical University Cancer Institute and Hospital	Completed	No outcome recorded
Phase 2/3	NCT05253066	Feb → Jul 2022	breast neoplasm	Shengjing Hospital	Unknown	No outcome recorded
Phase 2/3	NCT01648608	Jan → Dec 2012	breast cancer	Tianjin Medical University	Unknown	No outcome recorded
Phase 340 trials · 5 met primary · 12 missed
Phase 3	NCT07153757	Sep 2025 → Sep 2033 expected	female breast carcinoma	Fudan University	Not yet recruiting	No outcome recorded
Phase 3	NCT07005557	Jun 2025 → May 2030 expected	breast cancer	Fudan University	Not yet recruiting	No outcome recorded
Phase 3	NCT06223698	May 2025 → May 2032 expected	breast cancer	Region Örebro County	Not yet recruiting	No outcome recorded
Phase 3	NCT06492616	Sep 2024 → Aug 2029 expected	breast cancer	Stemline Therapeutics, Inc.	Recruiting	No outcome recorded
Phase 3	NCT06380751	Aug 2024 → Dec 2029 expected	breast cancer	AstraZeneca	Recruiting	No outcome recorded
Phase 3	NCT06507618	Jul 2024 → Jun 2029 expected	female breast carcinoma	University of Virginia	Recruiting	No outcome recorded
Phase 3	NCT06313983	Jan 2022 → Dec 2025 overdue	breast cancer	Tianjin Hemay Pharmaceutical Co., Ltd	Recruiting	No outcome recorded
Phase 3	NCT04975308	Oct 2021 → Jun 2024 overdue	breast cancer, metastatic malignant neoplasm	Eli Lilly and Company	Active not recruiting	No outcome recorded
Phase 3	NCT04460807	Feb 2020 → Apr 2023	ovarian cancer	Ente Ospedaliero Ospedali Galliera	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT03137368	Aug 2018 → Oct 2023	—	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Unknown	No outcome recorded
Phase 3	NCT03079011	Mar 2017 → Apr 2021	breast cancer	UNICANCER	Completed	Met primary
Phase 3	NCT02532400	Mar 2016 → Mar 2019	breast cancer	Ruijin Hospital	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT02404051	Dec 2015 → Jan 2018	hormone receptor-positive breast cancer, secondary malignant neoplasm	Consorzio Oncotech	Unknown	No outcome recorded
Phase 3	NCT02344472	Sep 2015 → Jan 2025	breast cancer	University of Ulm	Unknown	No outcome recorded
Phase 3	NCT02115282	Mar 2014 → May 2020 overdue	Her2-receptor negative breast cancer, breast adenocarcinoma, female breast carcinoma	National Cancer Institute (NCI)	Active not recruiting	Missed primary
Phase 3	NCT02028507	Mar 2014 → Jan 2019	breast cancer	Spanish Breast Cancer Research Group	Completed	Missed primary
Phase 3	NCT01950182	Sep 2013 → May 2020	breast cancer	Sun Yat-sen University	Completed	No outcome recorded
Phase 3	NCT02918084	Jun 2013 → Jun 2028 expected	breast cancer	IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy	Active not recruiting	No outcome recorded
Phase 3	NCT01638247	Aug 2012 → May 2018	male breast carcinoma	GBG Forschungs GmbH	Completed	No outcome recorded
Phase 3	NCT01626222	Jun 2012 → Nov 2013	breast cancer	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01303679	Jun 2010 → Jun 2014	breast cancer	ARCAGY/ GINECO GROUP	Terminated	Missed primary
Phase 3	NCT00893061	Mar 2009 → Apr 2012	breast cancer	Centre Oscar Lambret	Completed	No outcome recorded
Phase 3	NCT00902954	Mar 2008 → Jun 2010	breast cancer	Fudan University	Unknown	No outcome recorded
Phase 3	NCT00659373	Dec 2007 → Dec 2014	breast cancer, sleep disorder	ETOP IBCSG Partners Foundation	Completed	Missed primary
Phase 3	NCT00541086	Mar 2007 → Jul 2020	breast cancer	Gruppo Italiano Mammella (GIM)	Unknown	Missed primary
Phase 3	NCT00265759	Jan 2006 → Aug 2012	breast cancer	Alliance for Clinical Trials in Oncology	Completed	No outcome recorded
Phase 3	NCT00143390	Apr 2005 → Dec 2010	breast neoplasm	Pfizer	Completed	No outcome recorded
Phase 3	NCT00083174	Dec 2004 → Mar 2011	breast cancer	NCIC Clinical Trials Group	Completed	Met primary
Phase 3	NCT00066690	Dec 2003 → May 2014	estrogen-receptor positive breast cancer, female breast carcinoma, progesterone-receptor positive breast cancer	ETOP IBCSG Partners Foundation	Completed	Missed primary
Phase 3	NCT00066703	Nov 2003 → Mar 2011	breast cancer	ETOP IBCSG Partners Foundation	Completed	Met primary
Phase 3	NCT00066807	Aug 2003 → Dec 2006	breast cancer	ETOP IBCSG Partners Foundation	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00066573	Jun 2003 → Nov 2010	breast cancer	NCIC Clinical Trials Group	Completed	Missed primary
Phase 3	NCT00279448	Jan 2002 → Nov 2008	breast neoplasm	Pfizer	Completed	No outcome recorded
Phase 3	NCT00032136	Dec 2001 → Apr 2009	breast cancer	Cancer Research Campaign Clinical Trials Centre	Completed	Missed primary
Phase 3	NCT01237327	Nov 2001 → Dec 2007	breast cancer	Pfizer	Completed	Missed primary
Phase 3	NCT00036270	Aug 2001 → Oct 2008	breast neoplasm	Pfizer	Completed	Missed primary
Phase 3	NCT00016432	May 2001 → Oct 2003	female breast carcinoma	NSABP Foundation Inc	Completed	Missed primary
Phase 3	NCT00003418	Feb 1998 → ?	breast cancer	International Collaborative Cancer Group	Unknown	Met primary
Phase 3	NCT00038467	Feb 1998 → Jun 2003	breast cancer	Pfizer	Completed	Met primary
Phase 3	NCT00002777	May 1996 → Dec 2002	breast cancer	European Organisation for Research and Treatment of Cancer - EORTC	Completed	Missed primary

Phase 49 trials
Phase 4	NCT05362760	Apr 2022 → Apr 2029 expected	hormone receptor-positive breast cancer	University of Ulm	Recruiting	No outcome recorded
Phase 4	NCT03948568	Sep 2019 → Jun 2021	female breast carcinoma	Ottawa Hospital Research Institute	Completed	No outcome recorded
Phase 4	NCT03238703	Sep 2018 → Mar 2023	Her2-receptor negative breast cancer, breast carcinoma in situ, female breast carcinoma, invasive breast carcinoma	Fred Hutchinson Cancer Center	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT03355157	Mar 2018 → Aug 2024	breast cancer	GBG Forschungs GmbH	Completed	No outcome recorded
Phase 4	NCT02248571	Aug 2014 → Aug 2017	female breast carcinoma, hormone receptor-positive breast cancer	iOMEDICO AG	Completed	No outcome recorded
Phase 4	NCT01743560	Jan 2013 → Aug 2016	estrogen-receptor positive breast cancer	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01553903	Dec 2011 → May 2013	breast cancer	Institut Claudius Regaud	Completed	No outcome recorded
Phase 4	NCT01176916	Feb 2011 → Nov 2018	breast neoplasm	Pfizer	Completed	No outcome recorded
Phase 4	NCT01127295	Jun 2010 → Dec 2017	hormone receptor-positive breast cancer	Institut Claudius Regaud	Completed	No outcome recorded
Phase not applicable5 trials
—	NCT06235931	Feb 2024 → Dec 2025 overdue	breast neoplasm	Second Affiliated Hospital of Soochow University	Recruiting	No outcome recorded
—	NCT02109913	Mar 2014 → Jan 2021	hormone receptor-positive breast cancer	Amsterdam UMC, location VUmc	Unknown	No outcome recorded
—	NCT01720602	Nov 2012 → Mar 2015	male breast carcinoma	University of Washington	Completed	No outcome recorded
—	NCT01655004	Aug 2012 → Jun 2017	breast carcinoma	National University Hospital, Singapore	Unknown	No outcome recorded
—	NCT01385280	Feb 2011 → Jan 2013	estrogen-receptor positive breast cancer, female breast carcinoma, progesterone-receptor positive breast cancer	University of Arizona	Completed	No outcome recorded
Comparator or background therapy152 trials
Phase 0	NCT04088032 Background	Oct 2019 → Dec 2020	female breast carcinoma, hormone receptor-positive breast cancer	Alison Stopeck	Withdrawn	No outcome recorded
Phase 1	NCT06218303 Background	Feb 2024 → Aug 2026 overdue	ductal breast carcinoma in situ	Finn, Olivera, PhD	Recruiting	No outcome recorded
Phase 1	NCT05307705 Background	May 2022 → Dec 2026 expected	breast cancer	Eli Lilly and Company	Recruiting	No outcome recorded
Phase 1	NCT04572295 Background	Oct 2020 → Jun 2026	breast neoplasm	Eisai Inc.	Completed	No outcome recorded
Phase 1	NCT03846583 Background	Jun → Sep 2020	breast cancer	Dana-Farber Cancer Institute	Withdrawn	No outcome recorded Stop: Enrollment
Show all 152 trials opens the full record — a long page

News releases announcing trial results or a regulatory action · 11

Date	Issuer	Release
2021-12-08	Taizhou EOC Pharma Co., Ltd.	Results 亿腾景昂1类新药III期临床研究入选第44届SABCS eocpharma.com ↗ 结果显示，恩替诺特联合依西美坦治疗可显著改善激素受体阳性乳腺癌患者无进展生存期，在客观应答率和疾病控制率等方面优于依西美坦单药治疗，且患者安全性和耐受性良好。
2021-11-20	Taizhou EOC Pharma Co., Ltd.	Results 亿腾景昂临床III期研究成果入选第44届圣安东尼奥乳腺癌大会（SABCS） eocpharma.com ↗ 结果显示，恩替诺特联合依西美坦对比安慰剂联合依西美坦可以显著改善经内分泌治疗失败的HR阳性、HER-2阴性晚期乳腺癌患者的PFS，差异具有统计学显著性，且患者安全性和耐受性良好。
2020-05-21	Syndax Pharmaceuticals	Results ECOG-ACRIN Provides Syndax Pharmaceuticals With Results of Phase 3 E2112 Trial of Entinostat Plus Exemestane in Patients with HR+, HER2- Breast Cancer syndax.com ↗ The trial did not achieve the primary endpoint of demonstrating a statistically significant overall survival (OS) benefit over hormone therapy alone.
2019-12-03	Great Novel Therapeutics Biotech & Medicals Corporation	Regulatory 西達本胺晚期乳癌第二適應症中國獲批 com.tw ↗ 11月29日，「西達本胺」聯合諾曼癌素 (exemestane, aromasin®)用於治療既往內分泌療法失敗或復發的賀爾蒙受體陽性(ER+)、Her-2陰性不可手術晚期乳癌適應症，已經獲得中國NMPA批准取得藥證。
2019-04-29	Great Novel Therapeutics Biotech & Medicals Corporation	Results 西達本胺樞紐三期結果正面榮登刺胳針腫瘤學期刊 com.tw ↗ 他指出，從本次研究結果顯示，試驗組與對照組相比，中位的PFS值分別為7.4個月和3.8個月，具有統計顯著差異。
2018-10-25	Syndax Pharmaceuticals	Results Syndax to Host Conference Call to Provide Update on the Phase 3 Breast Cancer Trial (E2112) and to Announce its Registration Trial of Entinostat with Keytruda in PD-(L)1 Refractory Non-Small Cell Lung Cancer syndax.com ↗ The trial did not achieve the statistical hurdle for the first primary endpoint of improving progression-free survival (PFS) that would have provided the earliest regulatory filing opportunity.
2018-10-22	Great Novel Therapeutics Biotech & Medicals Corporation	Results 西達本胺晚期乳癌樞紐三期中國解盲達標 com.tw ↗ 達到臨床試驗設計的主要療效指標終點、以及安全性符合預期。
2018-10-05	Zydus Lifesciences Limited	Regulatory Zydus receives final approval from the USFDA for Exemestane Tablets zyduslife.com ↗ Zydus Cadila has received the final approval from the USFDA to market Exemestane Tablets, (US RLD – AROMASIN ® Tablets), 25 mg.
2017-08-24	Novartis Pharmaceuticals	Regulatory Novartis Kisqali® (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor novartis.com ↗
2017-06-23	Novartis Pharmaceuticals	Regulatory Novartis Kisqali® (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor novartis.com ↗ The CHMP recommendation of combining Kisqali with any aromatase inhibitor means that, if approved, oncologists could prescribe Kisqali with letrozole, anastrozole or exemestane, giving them the discretion to select the therapy they believe is most appropriate for each individual patient.
2017-04-17	Chipscreen Biosciences, Ltd.	Regulatory Phase III clinical trial of breast cancer approved by Taiwan TFDA in Chidamide chipscreen.com ↗ the application of Chidamide combined with aromasin? for the third phase of clinical trials of advanced breast cancer with hormone receptor positive and HER-2 negative was approved by Taiwan TFDA on April 07, 2017

All press releases naming this drug 12 releases

Date	Issuer	Release
2021-12-08	Taizhou EOC Pharma Co., Ltd.	亿腾景昂1类新药III期临床研究入选第44届SABCS eocpharma.com ↗
2021-11-20	Taizhou EOC Pharma Co., Ltd.	亿腾景昂临床III期研究成果入选第44届圣安东尼奥乳腺癌大会（SABCS） eocpharma.com ↗
2020-05-21	Syndax Pharmaceuticals	ECOG-ACRIN Provides Syndax Pharmaceuticals With Results of Phase 3 E2112 Trial of Entinostat Plus Exemestane in Patients with HR+, HER2- Breast Cancer syndax.com ↗
2019-12-03	Great Novel Therapeutics Biotech & Medicals Corporation	西達本胺晚期乳癌第二適應症中國獲批 com.tw ↗
2019-04-29	Great Novel Therapeutics Biotech & Medicals Corporation	西達本胺樞紐三期結果正面榮登刺胳針腫瘤學期刊 com.tw ↗
2018-10-25	Syndax Pharmaceuticals	Syndax to Host Conference Call to Provide Update on the Phase 3 Breast Cancer Trial (E2112) and to Announce its Registration Trial of Entinostat with Keytruda in PD-(L)1 Refractory Non-Small Cell Lung Cancer syndax.com ↗
2018-10-22	Great Novel Therapeutics Biotech & Medicals Corporation	西達本胺晚期乳癌樞紐三期中國解盲達標 com.tw ↗
2018-10-11	Upsher-Smith Laboratories	Upsher-Smith Launches Generic Version of Aromasin (exemestane) Tablets - upsher-smith.com ↗
2018-10-05	Zydus Lifesciences Limited	Zydus receives final approval from the USFDA for Exemestane Tablets zyduslife.com ↗
2017-08-24	Novartis Pharmaceuticals	Novartis Kisqali® (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor novartis.com ↗
2017-06-23	Novartis Pharmaceuticals	Novartis Kisqali® (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor novartis.com ↗
2017-04-17	Chipscreen Biosciences, Ltd.	Phase III clinical trial of breast cancer approved by Taiwan TFDA in Chidamide chipscreen.com ↗

Evidence & citations 17 cited values

Every value below carries the sentence it was read from. 327 sources stand behind the page.

Field	Value	Cited text
Known as	exemestane	“Aromatase inhibitor (anastrozole or exemestane or letrozole) oral daily tablet, or Selective Estrogen Receptor Modulator (SERM) such as tamoxifen oral daily tablet or...” NCT03820830 ↗ 322 “This treatment consisted of any aromatase inhibitor (e.g. letrozole or exemestane), administered intravenously in Cohort A Groups daily for either 18 (if 6 doses of WT1...” NCT01220128 ↗ “Options include tamoxifen (20 mg daily), aromatase inhibitors (letrozole 2.5 mg daily, anastrozole 1 mg daily, or exemestane 25 mg daily), or fulvestrant (500 mg...” NCT07708194 ↗ “Aromatase inhibitor of the investigator's choice (letrozole, anastrozole, or exemestane) will be provided orally once daily until unacceptable toxicity, documentation of...” NCT01446159 ↗ “Endocrine therapy is determined by the doctor, including any kind of letrozole, anastrozole, exemestane, fulvestrant, tamoxifen, toremifene, combined with or without drugs or...” NCT03204734 ↗ “Letrozole：2.5mg，q4w or Anastrozole：1mg，q4w or Exemestane：25mg，q4w or Fulvestrant:Patients will receive intramuscular Fulvestrant on day 1 and day 15 of the first cycle and then...” NCT07810088 ↗ “Endocrine therapy (physician's choice based on prior administered agent including tamoxifen, exemestane, fulvestrant, anastrozole, or letrozole). Endocrine therapy must be...” NCT03184090 ↗ “Tamoxifen 20 mg daily, or letrozole 2.5 mg daily, or anastrozole 1 mg daily, or exemestane 25 mg daily (male patients will be treated with tamoxifen 20 mg daily) for a total...” NCT03081234 ↗ “Postmenopausal patients: Letrozole (2.5 mg, orally, once daily, for 5 years) or Anastrozole (1 mg, orally, once daily, for 5 years) or Exemestane (25 mg, orally, once daily,...” NCT07153757 ↗ “Subjects will receive standard therapy with an aromatase inhibitor (exemestane, anastrozole, or letrozole), combined with the experimental treatment of abemaciclib and durvalumab” NCT04088032 ↗ “Letrozole 2.5 mg by mouth daily, or anastrozole 1 mg by mouth daily, exemestane 25 mg by mouth daily, tamoxifen 20 mg by mouth daily, for a total duration of at least 60 months.” NCT03078751 ↗ Show 312 more sources
Known as	Aromasin	“A Phase 4, Open-Label Exemestane Adjuvant Safety Surveillance Program: Adjuvant Exemestane (Aromasin) Treatment Following Previous Treatment With Tamoxifen in Postmenopausal...” NCT00649090 ↗ 8 “aromatase inhibitors ( letrozole 2.5 mg PO per day or Anastrozole 1 mg PO per day or aromasin 25 mg PO per day) if post-menopausal, if premenopausal leutnising hormone...” NCT04012918 ↗ “Endocrine Therapy: Exemestane (Aromasin®), Letrozole (Femara®), or Anastrozole (Arimidex®)” NCT03846583 ↗ “A commercial supply of exemestane (Aromasin) will be provided.” NCT00261027 ↗ “IM or Oral Exemestane (Aromasin) in Postmenopausal Women” NCT00040014 ↗ “Aromasin® (exemestane) 25 mg/day PO” NCT00828854 ↗ “exemestane (Aromasin®)” NCT00508586 ↗ “exemestane (Aromasin®)” NCT00174343 ↗ NCT01176916 ↗
Known as	Aromasin (exemestane)	“Aromasin (exemestane)” NCT00240071 ↗ 1 “Aromasin (exemestane)” NCT01897441 ↗
Known as	Aromasin, exemestane, Pfizer	“Aromasin®, exemestane, Pfizer” NCT00935558 ↗
Known as	Baby Exemestane	“Randomized Double Blind Phase II Trial of Baby Exemestane vs Baby Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.” NCT06364267 ↗
Known as	babyexe	“The purpose of the study is to to compare low dose of exemestane (babyexe) versus low dose of tamoxifen (babytam) in terms of change of quality of life from baseline to 12 months.” NCT06364267 ↗
Known as	EXE	“We hypothesized that exemestane (EXE) would reduce mammographic breast density and have unique effects on biomarkers of bone and lipid metabolism.” PMID 21221773 ↗ Jan 2011
Known as	Exemestane (Aromasin)	“Exemestane (Aromasin)” NCT06218303 ↗
Known as	Exemestane Tablets	“Drug: Exemestane Tablets” NCT04906395 ↗
Known as	Exemestano	ChEMBL registry synonym — accepted as the source's own label CHEMBL1200374 ↗
Known as	FCE-24304	ChEMBL registry synonym — accepted as the source's own label CHEMBL1200374 ↗
Known as	NSC-758907	ChEMBL registry synonym — accepted as the source's own label CHEMBL1200374 ↗
Known as	PNU-155971	ChEMBL registry synonym — accepted as the source's own label CHEMBL1200374 ↗
Action	Inhibit	“Hormone therapy using exemestane or tamoxifen may fight cancer by blocking the uptake of estrogen.” NCT00002777 ↗ 1 “Cytochrome P450 19A1 inhibitor” CHEMBL1200374 ↗
Modality	Small molecule	“the steroidal aromatase inactivator exemestane versus the antiestrogen tamoxifen” PMID 18794551 ↗ Sep 2008
Route	Oral	“Patients were randomly assigned to receive exemestane 25 mg or tamoxifen 20 mg orally once daily until disease progression or unacceptable toxicity occurred.” PMID 18794551 ↗ Sep 2008
Target	CYP19A1	“Cytochrome P450 19A1 inhibitor” CHEMBL1200374 ↗